CareDx Q3 2026 net income rises to $19.29 million year-over-year; Q3 2026 revenue climbs 39% to $139.36 million year-over-year
Bitget2026/10/29 20:06- CareDx’s third-quarter 2026 GAAP net income rose year-over-year to $19.29 million.
- Revenue climbed 39% year-over-year to $139.36 million, while Testing Services revenue jumped 65% to $119.19 million.
- Naveris acquisition closed July 1 for $160 million in cash, with up to $100 million in contingent consideration.
- Full-year 2026 revenue guidance increased to $520 million–$530 million from $490 million–$500 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
